A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience

Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, is approved as monotherapy or in combination with methotrexate for treating adults with moderate-to-severe active rheumatoid arthritis (RA) and provides improvements in clinical signs, symptoms and patient-reported outcomes. Currentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Peter C., Laedermann, Cedric, Alten, Rieke, Feist, Eugen, Choy, Ernest, Haladyj, Ewa, De La Torre, Inmaculada, Richette, Pascal, Finckh, Axel, Tanaka, Yoshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342289/
https://www.ncbi.nlm.nih.gov/pubmed/37445562
http://dx.doi.org/10.3390/jcm12134527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342289/
https://www.ncbi.nlm.nih.gov/pubmed/37445562
http://dx.doi.org/10.3390/jcm12134527

Ejemplares similares